Posted by Michael Wonder on 14 Dec 2023
Kyverna Therapeutics granted FDA fast track designation for KYV-101 in the treatment of patients with refractory myasthenia gravis
13 December 2023 - KYV-101 is a fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven auto-immune diseases.
Kyverna Therapeutics today announced it received fast track designation by the US FDA for its autologous, fully human CD19 chimeric antigen receptor T-cell product candidate, KYV-101, to be used for the treatment of myasthenia gravis.
